Drug intelligence / Profile preview

MRT5407

Development stage: Phase 2
Lead developer: Sanofi Pasteur
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MRT5407 is an investigational quadrivalent messenger RNA (mRNA) vaccine developed by Sanofi for the prevention of influenza in adults. The vaccine utilizes an mRNA platform acquired from Translate Bio to encode influenza virus antigens, specifically designed to elicit immune responses against four distinct strains of the influenza virus. It is formulated as a liquid frozen solution for intramuscular injection. MRT5407 is currently being evaluated in Phase 1/2 clinical trials to assess its safety and immunogenicity in comparison to standard-dose, high-dose, and recombinant quadrivalent influenza vaccines.

Other names: Quadrivalent Influenza mRNA Vaccine MRT5407Sanofi Pasteur influenza mRNA vaccine

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on MRT5407.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRT5407.

Explore the full profile